Short answer
Gilead Sciences (GILD) filed its Q2 2025 10-Q quarterly report on Aug 7, 2025 for the quarter ended Jun 30, 2025. Quarterly revenue was $7.1B (up 1.8% year over year) with net income of $2.0B.
Q2 2025 key financials · XBRL
- Revenue
- $7.1B
- +1.8% YoY · +6.2% QoQ
- Net income
- $2.0B
- +21.4% YoY · +49.0% QoQ
- Operating margin
- 34.9%
- EPS (diluted)
- $1.57
- +21.7% YoY · +51.0% QoQ
Source: XBRL data from the Gilead Sciences (GILD) Q2 2025 10-Q on SEC EDGAR. USD.
Gilead Sciences Q2 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- No information on cash position, operating cash flow, or capital deployment changes
- No management commentary on outlook, guidance, or headwinds presented
Risk Factors
- New risk: FDA "boxed warning" on CAR T therapies in Jan 2024 for secondary T-cell malignancies, impacting Yescarta and Tecartus labeling
- Updated regulatory risk: IRA increasing 2023-25 Medicare discounts and rebates, reducing profitability through new Part D payment rules
- Legal risk: Uncertain outcome of litigation and enforcement actions around 340B contract pharmacy integrity initiative, including recent court decisions
- Operational risk: Supply chain disruption risks for cell therapies due to reliance on certified apheresis centers and complex manufacturing needs
- Financial risk: Sales dependent on 3 wholesalers accounting for ~90% U.S. distribution, causing volatile quarterly revenues from inventory mismatches
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Gilead Sciences quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.